Robots for this group tickers :
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA) - 30-day Annualized Return +73%
Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) - 30-day Annualized Return +33%
Urology companies, comprising EDAP (EDAP), Teleflex (TFX), and UroGen Pharma (URGN), have shown a remarkable +6.67% increase in performance over the last week. In this analysis, we delve into various indicators and metrics to better understand the current landscape and individual trajectories within this thematic sector.
Stock Outlook and Indicators
Bollinger bands and Fear & Greed Index
The Negative Outlook for these stocks is supported by the BollingerBands Indicator and the Stock Fear & Greed Index. Tickeron predicts a further decline of more than 4.00% within the next week with a likelihood of 70%. The daily ratio of advancing to declining volumes over the last week was 1 to 1.36, indicating a certain level of market indecision.
MACD Indicator
Two stocks within this thematic group have confirmed a negative outlook based on the Moving Average Convergence Divergence (MACD) indicator, with an average accuracy of 81%.
Market Capitalization Insights
The average market capitalization across the urology theme stands at 3.6 billion USD. Notably, TFX boasts the highest valuation at 10.3 billion USD, while SPHS holds the lowest valuation at 344.7 thousand USD.
Price Performance
Highs and Lows
The average weekly, weekly, and quarterly price growth across all urology stocks was 6.04%, 8.52%, and 10.75%, respectively. EDAP experienced the highest price growth at 14.42%, while TFX saw a notable fall of -0.93%. This underlines the dynamic nature of the urology theme.
Recent Declines
On 8/18/23, UroGen Pharma (URGN) experienced a significant decline of -13.11%, indicating a potential downtrend continuation. Similarly, on 1/12/23, Teleflex (TFX) recorded a decline of -6.89%.
Volume Trends
Volume Growth Metrics
The average weekly volume growth across all urology stocks was 58.89%, with weekly and quarterly averages at 45.22% and 9.77%, respectively. This suggests heightened market activity in the short term.
Record-Breaking Volumes
On 12/19/23, EDAP TMS SA saw a record-breaking daily growth of 1,669% of the 65-Day Volume Moving Average. Similar record-breaking volume growth was noted for UroGen Pharma on 12/16/23 (523%) and 4/26/23 (399%).
Individual Stock Analysis
EDAP (EDAP)
EDAP's Stochastic Oscillator is in the overbought zone for 2 days, suggesting a potential price pullback. The current price of $6.11 is below the lowest support line found by A.I. at $9.34. Despite this, the stock experienced a +19% uptrend from 12/15/23 to 01/19/24.
Teleflex (TFX)
The Momentum Indicator for TFX turned positive on January 18, 2024, indicating a potential upward trend. The odds of a move higher are at 67%. The current price of $251.41 is trading between $320.82 resistance and $248.13 support lines. TFX experienced a -3% downtrend from 12/15/23 to 01/19/24.
UroGen Pharma (URGN)
URGN's RSI Indicator recovered from the overbought zone on December 15, 2023. This signals a potential shift from an upward to a downward trend, with a 90% probability of a move down. The current price of $15.00 is trading between $17.11 support and $12.84 resistance lines. The week of 12/15/23 to 01/19/24 saw a -2% downtrend, but the week of 01/11/24 to 01/19/24 shows a +5% uptrend.
Summary
In summary, while the urology theme has seen an overall positive performance, individual stock analyses reveal nuances that investors should consider. Monitoring key indicators like the MACD, Stochastic Oscillator, and RSI can provide valuable insights into potential price movements. As always, investors should conduct thorough research and consider various factors before making investment decisions in this dynamic sector.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EDAP advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 47 cases where EDAP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The 10-day RSI Indicator for EDAP moved out of overbought territory on April 10, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on May 09, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on EDAP as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EDAP turned negative on April 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
EDAP moved below its 50-day moving average on May 03, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EDAP crossed bearishly below the 50-day moving average on April 29, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.581) is normal, around the industry mean (14.370). EDAP's P/E Ratio (100.000) is considerably higher than the industry average of (28.511). EDAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). EDAP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (4.303) is also within normal values, averaging (36.746).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors